Abstract:
Objective This study aimed to evaluate the effects of goal-directed fluid therapy by the FloTrac/Vigileo system in patients undergoing hepatoma surgery and to find the best fluid therapy.
Methods Eighty hepatocellular carcinoma patients were included and randomly divided into two groups based on treatment: conventional fluid therapy (group N) and goal-directed fluid therapy (group G). The vital signs of all patients were routinely monitored, including the electrocardiogram, heart rate (HR), saturation of peripheral oxygen, mean arterial pressure (MAP), and central venous pressure (CVP). In group G, the FloTrac/Vigileo system was used to obtain the stroke volume variation (SVV) and cardiac index (CI). As aforementioned, group N received conventional fluid therapy, whereas group G received fluid therapy based on the SVV, CVP, and CI. The duration of surgery, crystalloid requirements, colloid requirements, and urinary output were recorded. MAP, HR, CVP, CI, and SVV were recorded during the surgery. The oxygen delivery (DO2), oxygen consumption (VO2), and oxygen extraction ratio (ERO2) were examined after anesthesia induction and at the end of the surgery.
Results The crystal volume in group N was higher than that in group G (P < 0.05).The colloid number and amount of urine in group G was higher than that in group N (P < 0.05). The MAP, CVP, and CI after anesthesia induction were lower than that upon arrival at the operating room. The MAP, CVP, and CI in group G recovered to normal earlier than those in group N. The SVV was 10.8% at the moment of porta hepatic blockage in group N, and then became lower than normal thereafter. From the beginning to the end of surgery, the SVV in group G was lower than normal. The VO2 and ERO2 at the end of the surgery was lower than that upon anesthesia induction in group N, and higher than that upon anesthesia induction in group G (P < 0.05). The DO2, VO2, and ERO2 at the end of the surgery in group G was higher than those in group N (P < 0.05).
Conclusion Goal-directed fluid therapy by the FloTrac/Vigileo system enables real-time and effective monitoring, maintains hemodynamic stability, as well as ensures adequate tissue perfusion and optimal DO2 and VO2. This treatment method is more effective than conventional fluid therapy.